Key Takeaways
- • Amperos Health closed a $16 million Series A funding round led by Bessemer Venture Partners, with participation from Uncork Capital and Neo, bringing total capital raised to $21 million.
- • The AI-native denial management platform has already helped customers recover approximately $700 million in outstanding claims annually, though the addressable market for denied claims exceeds $262 billion per year.
- • Initial claims denials reached nearly 12% in 2024, with healthcare providers spending over $26 billion annually on denied claim recovery, creating significant operational inefficiency that Amperos targets.
- • Amperos plans to expand its platform with additional modules addressing prior authorization and insurance verification later in 2026, extending beyond core denial management into adjacent RCM functions.
- • Sofia Guerra, partner at Bessemer Venture Partners, highlighted the company's technical approach and strong customer satisfaction as key investment factors.
Summary
Amperos Health, an artificial intelligence-focused revenue cycle management (RCM) platform, announced the close of a $16 million Series A funding round on April 22, 2026. The round was led by Bessemer Venture Partners with participation from returning investors Uncork Capital and Neo. This Series A brings Amperos' total funding to $21 million, including a prior $4.2 million seed round closed with Uncork Capital, Neo, and Nebular, along with strategic angel investors from OpenAI, Twilio, and Stripe.
Amperos positions itself as healthcare's first AI-native denial management and revenue recovery solution, designed to automate end-to-end denial resolution for healthcare provider RCM teams. The platform is fully HIPAA-compliant and incorporates bank-level security infrastructure. According to Sofia Guerra, partner at Bessemer Venture Partners, the firm was attracted to Amperos' quality, technical approach, and demonstrated customer results. "When you get on the phone with a customer and they have raving reviews, that's where you really pay attention," Guerra stated.
The company's growth reflects a significant pain point within healthcare operations. Initial claims denials reached nearly 12% in 2024, with providers collectively spending more than $26 billion annually on denied claim recovery processes. Amperos Health CEO and co-founder Michal Miernowski noted that the company has helped customers recover approximately $700 million in outstanding claims per year, yet the total denied revenue in the industry exceeds $262 billion annually. "We're only really scratching the surface," Miernowski said, highlighting the substantial market opportunity ahead.
The new capital will be deployed to scale Amperos' team and expand its platform capabilities. Miernowski indicated that the company plans to launch additional modules later in 2026, including prior authorization and insurance verification tools, extending Amperos' reach across multiple RCM operational areas beyond core denial management.
Amperos positions itself as healthcare's first AI-native denial management and revenue recovery solution, designed to automate end-to-end denial resolution for healthcare provider RCM teams. The platform is fully HIPAA-compliant and incorporates bank-level security infrastructure. According to Sofia Guerra, partner at Bessemer Venture Partners, the firm was attracted to Amperos' quality, technical approach, and demonstrated customer results. "When you get on the phone with a customer and they have raving reviews, that's where you really pay attention," Guerra stated.
The company's growth reflects a significant pain point within healthcare operations. Initial claims denials reached nearly 12% in 2024, with providers collectively spending more than $26 billion annually on denied claim recovery processes. Amperos Health CEO and co-founder Michal Miernowski noted that the company has helped customers recover approximately $700 million in outstanding claims per year, yet the total denied revenue in the industry exceeds $262 billion annually. "We're only really scratching the surface," Miernowski said, highlighting the substantial market opportunity ahead.
The new capital will be deployed to scale Amperos' team and expand its platform capabilities. Miernowski indicated that the company plans to launch additional modules later in 2026, including prior authorization and insurance verification tools, extending Amperos' reach across multiple RCM operational areas beyond core denial management.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.